Key Raw Material for Cancer Cell Therapy: Importance of Patient-Tailored Cell Harvesting

Dr. Steven A. Rosenberg's research team at the U.S. National Cancer Institute (NCI) is conducting the NCT00068003 clinical protocol to collect leukocytes and tumor tissue from solid tumor patients and healthy donors. This clinical trial is not aimed at direct drug administration but serves as a foundational step to secure raw materials for next-generation cell therapies, including autologous tumor-infiltrating lymphocyte (TIL) and neoantigen-reactive T-cell therapies. The precise collection of effective cells derived from the tumor microenvironment is considered a critical process milestone that enables the production of high-quality cell therapies. The academic and commercial value is significant, as it provides both quantitative cell culture data and genomic analysis data for the discovery of tumor-specific receptors.

Approval of the First Solid Tumor TIL Therapy and Market Launch

This cell harvesting research has acted as a catalyst for opening the TIL therapy market for solid tumors, which activates T cells within the tumor to attack cancer cells. In fact, Amtagvi (lifileucel) developed by Iovance Biotherapeutics based on NCI technology received accelerated approval from the U.S. Food and Drug Administration (FDA) on February 16, 2024, as a treatment for metastatic melanoma. This marks the first approval of a T-cell therapy in the solid tumor field, and Amtagvi has shown rapid growth, recording approximately $264 million in annual sales in 2025. NCI's protocol supports the commercialization of high-value biopharmaceuticals and creates a virtuous cycle by providing real therapeutic alternatives in clinical settings.

Standardization Challenges in Cell Harvesting and Separation Processes

The NCI research team performs apheresis on patients and donors to isolate specific blood components and collects tissue through tumor resection. The harvested cells are then expanded in the laboratory into neoantigen-reactive TILs and used as targets for discovering tumor-specific T-cell receptors (TCRs). A major bottleneck in cell therapy production is maintaining consistent yield and quality of initial cells, and NCI's standardized protocol serves as a benchmark for addressing this issue. This process standardization is expected to significantly contribute to large-scale production and cost reduction by contract development and manufacturing organizations (CDMOs) in the future.

Data Acquisition for Next-Generation Immuno-Oncology Platforms

This clinical trial plays a crucial role as a database for accumulating individual immune response data to predict the efficacy of personalized immune checkpoint inhibitors and combination therapies for solid tumors. The research team analyzes the harvested cells to discover T-cell receptors targeting patient-specific cancer mutations and formulates strategies to suppress cancer recurrence at the acquisition trait level. In the long term, this technology will clearly serve as a foundation for expanding cell therapy indications beyond melanoma to gastrointestinal, lung, and breast cancers. For global biotechs developing commercial pipelines, it acts as a compass to reduce clinical design uncertainties and refine target molecules.